Live Breaking News & Updates on α4β7 Integrin Inhibitor

Stay updated with breaking news from α4β7 integrin inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab. ....

Sabyasachi Ghosh , Takeda Pharmaceuticals , Patients With Ulcerative Colitis , Outcomes From , Anti Tumor Necrosis Factor Therapy , Inflammatory Bowel , Front Med , Ulcerative Colitis , Inflammatory Bowel Disease , Dose Escalation , Loss Of Response , Antitumor Necrosis Factor Alpha Treatment , α4β7 Integrin Inhibitor ,